Pharma & Healthcare
Global Bladder Cancer Biologics Market Research Report 2026
- May 01, 26
- ID: 759434
- Pages: 121
- Figures: 126
- Views: 2
This report delivers a comprehensive overview of the global Bladder Cancer Biologics market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Bladder Cancer Biologics. The Bladder Cancer Biologics market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Bladder Cancer Biologics market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Bladder Cancer Biologics manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
AstraZenenca
Bristol-Myers Squibb Company
Chugai Pharmaceutical
Cold Genesys
Eli Lilly
Nighthawk Biosciences
Merck & Co
Mirati Therapeutics
OncoGenex
Pfizer
Roche Holding
Spectrum Pharmaceuticals
Taiho Pharmaceutical
Segment by Type
PD-1 Inhibitors
CTLA-4 Inhibitors
FGFR Inhibitors
Others
by Application
Hospital
Specialty Clinic
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Bladder Cancer Biologics manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Bladder Cancer Biologics sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
The report segments the global Bladder Cancer Biologics market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Bladder Cancer Biologics manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
AstraZenenca
Bristol-Myers Squibb Company
Chugai Pharmaceutical
Cold Genesys
Eli Lilly
Nighthawk Biosciences
Merck & Co
Mirati Therapeutics
OncoGenex
Pfizer
Roche Holding
Spectrum Pharmaceuticals
Taiho Pharmaceutical
Segment by Type
PD-1 Inhibitors
CTLA-4 Inhibitors
FGFR Inhibitors
Others
by Application
Hospital
Specialty Clinic
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Bladder Cancer Biologics manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Bladder Cancer Biologics sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
1 Bladder Cancer Biologics Market Overview
1.1 Product Definition
1.2 Bladder Cancer Biologics by Type
1.2.1 Global Bladder Cancer Biologics Market Value by Type: 2025 vs 2032
1.2.2 PD-1 Inhibitors
1.2.3 CTLA-4 Inhibitors
1.2.4 FGFR Inhibitors
1.2.5 Others
1.3 Bladder Cancer Biologics by Application
1.3.1 Global Bladder Cancer Biologics Market Value by Application: 2025 vs 2032
1.3.2 Hospital
1.3.3 Specialty Clinic
1.3.4 Other
1.4 Global Bladder Cancer Biologics Market Size Estimates and Forecasts
1.4.1 Global Bladder Cancer Biologics Revenue 2021–2032
1.4.2 Global Bladder Cancer Biologics Sales 2021–2032
1.4.3 Global Bladder Cancer Biologics Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Bladder Cancer Biologics Market Competition by Manufacturers
2.1 Global Bladder Cancer Biologics Sales Market Share by Manufacturers (2021–2026)
2.2 Global Bladder Cancer Biologics Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Bladder Cancer Biologics Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Bladder Cancer Biologics, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Bladder Cancer Biologics, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Bladder Cancer Biologics, Product Types and Applications
2.7 Global Key Manufacturers of Bladder Cancer Biologics, Date of Entry into the Industry
2.8 Global Bladder Cancer Biologics Market Competitive Situation and Trends
2.8.1 Global Bladder Cancer Biologics Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Bladder Cancer Biologics Players Market Share by Revenue
2.8.3 Global Bladder Cancer Biologics Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Bladder Cancer Biologics Market Scenario by Region
3.1 Global Bladder Cancer Biologics Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Bladder Cancer Biologics Sales by Region: 2021–2032
3.2.1 Global Bladder Cancer Biologics Sales by Region: 2021–2026
3.2.2 Global Bladder Cancer Biologics Sales by Region: 2027–2032
3.3 Global Bladder Cancer Biologics Revenue by Region: 2021–2032
3.3.1 Global Bladder Cancer Biologics Revenue by Region: 2021–2026
3.3.2 Global Bladder Cancer Biologics Revenue by Region: 2027–2032
3.4 North America Bladder Cancer Biologics Market Facts & Figures by Country
3.4.1 North America Bladder Cancer Biologics Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Bladder Cancer Biologics Sales by Country (2021–2032)
3.4.3 North America Bladder Cancer Biologics Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Bladder Cancer Biologics Market Facts & Figures by Country
3.5.1 Europe Bladder Cancer Biologics Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Bladder Cancer Biologics Sales by Country (2021–2032)
3.5.3 Europe Bladder Cancer Biologics Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Bladder Cancer Biologics Market Facts & Figures by Region
3.6.1 Asia Pacific Bladder Cancer Biologics Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Bladder Cancer Biologics Sales by Region (2021–2032)
3.6.3 Asia Pacific Bladder Cancer Biologics Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Bladder Cancer Biologics Market Facts & Figures by Country
3.7.1 Latin America Bladder Cancer Biologics Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Bladder Cancer Biologics Sales by Country (2021–2032)
3.7.3 Latin America Bladder Cancer Biologics Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Bladder Cancer Biologics Market Facts & Figures by Country
3.8.1 Middle East and Africa Bladder Cancer Biologics Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Bladder Cancer Biologics Sales by Country (2021–2032)
3.8.3 Middle East and Africa Bladder Cancer Biologics Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Bladder Cancer Biologics Sales by Type (2021–2032)
4.1.1 Global Bladder Cancer Biologics Sales by Type (2021–2026)
4.1.2 Global Bladder Cancer Biologics Sales by Type (2027–2032)
4.1.3 Global Bladder Cancer Biologics Sales Market Share by Type (2021–2032)
4.2 Global Bladder Cancer Biologics Revenue by Type (2021–2032)
4.2.1 Global Bladder Cancer Biologics Revenue by Type (2021–2026)
4.2.2 Global Bladder Cancer Biologics Revenue by Type (2027–2032)
4.2.3 Global Bladder Cancer Biologics Revenue Market Share by Type (2021–2032)
4.3 Global Bladder Cancer Biologics Price by Type (2021–2032)
5 Segment by Application
5.1 Global Bladder Cancer Biologics Sales by Application (2021–2032)
5.1.1 Global Bladder Cancer Biologics Sales by Application (2021–2026)
5.1.2 Global Bladder Cancer Biologics Sales by Application (2027–2032)
5.1.3 Global Bladder Cancer Biologics Sales Market Share by Application (2021–2032)
5.2 Global Bladder Cancer Biologics Revenue by Application (2021–2032)
5.2.1 Global Bladder Cancer Biologics Revenue by Application (2021–2026)
5.2.2 Global Bladder Cancer Biologics Revenue by Application (2027–2032)
5.2.3 Global Bladder Cancer Biologics Revenue Market Share by Application (2021–2032)
5.3 Global Bladder Cancer Biologics Price by Application (2021–2032)
6 Key Companies Profiled
6.1 AstraZenenca
6.1.1 AstraZenenca Company Information
6.1.2 AstraZenenca Description and Business Overview
6.1.3 AstraZenenca Bladder Cancer Biologics Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 AstraZenenca Bladder Cancer Biologics Product Portfolio
6.1.5 AstraZenenca Recent Developments/Updates
6.2 Bristol-Myers Squibb Company
6.2.1 Bristol-Myers Squibb Company Company Information
6.2.2 Bristol-Myers Squibb Company Description and Business Overview
6.2.3 Bristol-Myers Squibb Company Bladder Cancer Biologics Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Bristol-Myers Squibb Company Bladder Cancer Biologics Product Portfolio
6.2.5 Bristol-Myers Squibb Company Recent Developments/Updates
6.3 Chugai Pharmaceutical
6.3.1 Chugai Pharmaceutical Company Information
6.3.2 Chugai Pharmaceutical Description and Business Overview
6.3.3 Chugai Pharmaceutical Bladder Cancer Biologics Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Chugai Pharmaceutical Bladder Cancer Biologics Product Portfolio
6.3.5 Chugai Pharmaceutical Recent Developments/Updates
6.4 Cold Genesys
6.4.1 Cold Genesys Company Information
6.4.2 Cold Genesys Description and Business Overview
6.4.3 Cold Genesys Bladder Cancer Biologics Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Cold Genesys Bladder Cancer Biologics Product Portfolio
6.4.5 Cold Genesys Recent Developments/Updates
6.5 Eli Lilly
6.5.1 Eli Lilly Company Information
6.5.2 Eli Lilly Description and Business Overview
6.5.3 Eli Lilly Bladder Cancer Biologics Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Eli Lilly Bladder Cancer Biologics Product Portfolio
6.5.5 Eli Lilly Recent Developments/Updates
6.6 Nighthawk Biosciences
6.6.1 Nighthawk Biosciences Company Information
6.6.2 Nighthawk Biosciences Description and Business Overview
6.6.3 Nighthawk Biosciences Bladder Cancer Biologics Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Nighthawk Biosciences Bladder Cancer Biologics Product Portfolio
6.6.5 Nighthawk Biosciences Recent Developments/Updates
6.7 Merck & Co
6.7.1 Merck & Co Company Information
6.7.2 Merck & Co Description and Business Overview
6.7.3 Merck & Co Bladder Cancer Biologics Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Merck & Co Bladder Cancer Biologics Product Portfolio
6.7.5 Merck & Co Recent Developments/Updates
6.8 Mirati Therapeutics
6.8.1 Mirati Therapeutics Company Information
6.8.2 Mirati Therapeutics Description and Business Overview
6.8.3 Mirati Therapeutics Bladder Cancer Biologics Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Mirati Therapeutics Bladder Cancer Biologics Product Portfolio
6.8.5 Mirati Therapeutics Recent Developments/Updates
6.9 OncoGenex
6.9.1 OncoGenex Company Information
6.9.2 OncoGenex Description and Business Overview
6.9.3 OncoGenex Bladder Cancer Biologics Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 OncoGenex Bladder Cancer Biologics Product Portfolio
6.9.5 OncoGenex Recent Developments/Updates
6.10 Pfizer
6.10.1 Pfizer Company Information
6.10.2 Pfizer Description and Business Overview
6.10.3 Pfizer Bladder Cancer Biologics Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Pfizer Bladder Cancer Biologics Product Portfolio
6.10.5 Pfizer Recent Developments/Updates
6.11 Roche Holding
6.11.1 Roche Holding Company Information
6.11.2 Roche Holding Description and Business Overview
6.11.3 Roche Holding Bladder Cancer Biologics Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Roche Holding Bladder Cancer Biologics Product Portfolio
6.11.5 Roche Holding Recent Developments/Updates
6.12 Spectrum Pharmaceuticals
6.12.1 Spectrum Pharmaceuticals Company Information
6.12.2 Spectrum Pharmaceuticals Description and Business Overview
6.12.3 Spectrum Pharmaceuticals Bladder Cancer Biologics Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Spectrum Pharmaceuticals Bladder Cancer Biologics Product Portfolio
6.12.5 Spectrum Pharmaceuticals Recent Developments/Updates
6.13 Taiho Pharmaceutical
6.13.1 Taiho Pharmaceutical Company Information
6.13.2 Taiho Pharmaceutical Description and Business Overview
6.13.3 Taiho Pharmaceutical Bladder Cancer Biologics Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Taiho Pharmaceutical Bladder Cancer Biologics Product Portfolio
6.13.5 Taiho Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Bladder Cancer Biologics Industry Chain Analysis
7.2 Bladder Cancer Biologics Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Bladder Cancer Biologics Production Mode & Process Analysis
7.4 Bladder Cancer Biologics Sales and Marketing
7.4.1 Bladder Cancer Biologics Sales Channels
7.4.2 Bladder Cancer Biologics Distributors
7.5 Bladder Cancer Biologics Customer Analysis
8 Bladder Cancer Biologics Market Dynamics
8.1 Bladder Cancer Biologics Industry Trends
8.2 Bladder Cancer Biologics Market Drivers
8.3 Bladder Cancer Biologics Market Challenges
8.4 Bladder Cancer Biologics Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Bladder Cancer Biologics by Type
1.2.1 Global Bladder Cancer Biologics Market Value by Type: 2025 vs 2032
1.2.2 PD-1 Inhibitors
1.2.3 CTLA-4 Inhibitors
1.2.4 FGFR Inhibitors
1.2.5 Others
1.3 Bladder Cancer Biologics by Application
1.3.1 Global Bladder Cancer Biologics Market Value by Application: 2025 vs 2032
1.3.2 Hospital
1.3.3 Specialty Clinic
1.3.4 Other
1.4 Global Bladder Cancer Biologics Market Size Estimates and Forecasts
1.4.1 Global Bladder Cancer Biologics Revenue 2021–2032
1.4.2 Global Bladder Cancer Biologics Sales 2021–2032
1.4.3 Global Bladder Cancer Biologics Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Bladder Cancer Biologics Market Competition by Manufacturers
2.1 Global Bladder Cancer Biologics Sales Market Share by Manufacturers (2021–2026)
2.2 Global Bladder Cancer Biologics Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Bladder Cancer Biologics Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Bladder Cancer Biologics, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Bladder Cancer Biologics, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Bladder Cancer Biologics, Product Types and Applications
2.7 Global Key Manufacturers of Bladder Cancer Biologics, Date of Entry into the Industry
2.8 Global Bladder Cancer Biologics Market Competitive Situation and Trends
2.8.1 Global Bladder Cancer Biologics Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Bladder Cancer Biologics Players Market Share by Revenue
2.8.3 Global Bladder Cancer Biologics Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Bladder Cancer Biologics Market Scenario by Region
3.1 Global Bladder Cancer Biologics Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Bladder Cancer Biologics Sales by Region: 2021–2032
3.2.1 Global Bladder Cancer Biologics Sales by Region: 2021–2026
3.2.2 Global Bladder Cancer Biologics Sales by Region: 2027–2032
3.3 Global Bladder Cancer Biologics Revenue by Region: 2021–2032
3.3.1 Global Bladder Cancer Biologics Revenue by Region: 2021–2026
3.3.2 Global Bladder Cancer Biologics Revenue by Region: 2027–2032
3.4 North America Bladder Cancer Biologics Market Facts & Figures by Country
3.4.1 North America Bladder Cancer Biologics Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Bladder Cancer Biologics Sales by Country (2021–2032)
3.4.3 North America Bladder Cancer Biologics Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Bladder Cancer Biologics Market Facts & Figures by Country
3.5.1 Europe Bladder Cancer Biologics Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Bladder Cancer Biologics Sales by Country (2021–2032)
3.5.3 Europe Bladder Cancer Biologics Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Bladder Cancer Biologics Market Facts & Figures by Region
3.6.1 Asia Pacific Bladder Cancer Biologics Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Bladder Cancer Biologics Sales by Region (2021–2032)
3.6.3 Asia Pacific Bladder Cancer Biologics Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Bladder Cancer Biologics Market Facts & Figures by Country
3.7.1 Latin America Bladder Cancer Biologics Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Bladder Cancer Biologics Sales by Country (2021–2032)
3.7.3 Latin America Bladder Cancer Biologics Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Bladder Cancer Biologics Market Facts & Figures by Country
3.8.1 Middle East and Africa Bladder Cancer Biologics Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Bladder Cancer Biologics Sales by Country (2021–2032)
3.8.3 Middle East and Africa Bladder Cancer Biologics Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Bladder Cancer Biologics Sales by Type (2021–2032)
4.1.1 Global Bladder Cancer Biologics Sales by Type (2021–2026)
4.1.2 Global Bladder Cancer Biologics Sales by Type (2027–2032)
4.1.3 Global Bladder Cancer Biologics Sales Market Share by Type (2021–2032)
4.2 Global Bladder Cancer Biologics Revenue by Type (2021–2032)
4.2.1 Global Bladder Cancer Biologics Revenue by Type (2021–2026)
4.2.2 Global Bladder Cancer Biologics Revenue by Type (2027–2032)
4.2.3 Global Bladder Cancer Biologics Revenue Market Share by Type (2021–2032)
4.3 Global Bladder Cancer Biologics Price by Type (2021–2032)
5 Segment by Application
5.1 Global Bladder Cancer Biologics Sales by Application (2021–2032)
5.1.1 Global Bladder Cancer Biologics Sales by Application (2021–2026)
5.1.2 Global Bladder Cancer Biologics Sales by Application (2027–2032)
5.1.3 Global Bladder Cancer Biologics Sales Market Share by Application (2021–2032)
5.2 Global Bladder Cancer Biologics Revenue by Application (2021–2032)
5.2.1 Global Bladder Cancer Biologics Revenue by Application (2021–2026)
5.2.2 Global Bladder Cancer Biologics Revenue by Application (2027–2032)
5.2.3 Global Bladder Cancer Biologics Revenue Market Share by Application (2021–2032)
5.3 Global Bladder Cancer Biologics Price by Application (2021–2032)
6 Key Companies Profiled
6.1 AstraZenenca
6.1.1 AstraZenenca Company Information
6.1.2 AstraZenenca Description and Business Overview
6.1.3 AstraZenenca Bladder Cancer Biologics Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 AstraZenenca Bladder Cancer Biologics Product Portfolio
6.1.5 AstraZenenca Recent Developments/Updates
6.2 Bristol-Myers Squibb Company
6.2.1 Bristol-Myers Squibb Company Company Information
6.2.2 Bristol-Myers Squibb Company Description and Business Overview
6.2.3 Bristol-Myers Squibb Company Bladder Cancer Biologics Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Bristol-Myers Squibb Company Bladder Cancer Biologics Product Portfolio
6.2.5 Bristol-Myers Squibb Company Recent Developments/Updates
6.3 Chugai Pharmaceutical
6.3.1 Chugai Pharmaceutical Company Information
6.3.2 Chugai Pharmaceutical Description and Business Overview
6.3.3 Chugai Pharmaceutical Bladder Cancer Biologics Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Chugai Pharmaceutical Bladder Cancer Biologics Product Portfolio
6.3.5 Chugai Pharmaceutical Recent Developments/Updates
6.4 Cold Genesys
6.4.1 Cold Genesys Company Information
6.4.2 Cold Genesys Description and Business Overview
6.4.3 Cold Genesys Bladder Cancer Biologics Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Cold Genesys Bladder Cancer Biologics Product Portfolio
6.4.5 Cold Genesys Recent Developments/Updates
6.5 Eli Lilly
6.5.1 Eli Lilly Company Information
6.5.2 Eli Lilly Description and Business Overview
6.5.3 Eli Lilly Bladder Cancer Biologics Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Eli Lilly Bladder Cancer Biologics Product Portfolio
6.5.5 Eli Lilly Recent Developments/Updates
6.6 Nighthawk Biosciences
6.6.1 Nighthawk Biosciences Company Information
6.6.2 Nighthawk Biosciences Description and Business Overview
6.6.3 Nighthawk Biosciences Bladder Cancer Biologics Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Nighthawk Biosciences Bladder Cancer Biologics Product Portfolio
6.6.5 Nighthawk Biosciences Recent Developments/Updates
6.7 Merck & Co
6.7.1 Merck & Co Company Information
6.7.2 Merck & Co Description and Business Overview
6.7.3 Merck & Co Bladder Cancer Biologics Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Merck & Co Bladder Cancer Biologics Product Portfolio
6.7.5 Merck & Co Recent Developments/Updates
6.8 Mirati Therapeutics
6.8.1 Mirati Therapeutics Company Information
6.8.2 Mirati Therapeutics Description and Business Overview
6.8.3 Mirati Therapeutics Bladder Cancer Biologics Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Mirati Therapeutics Bladder Cancer Biologics Product Portfolio
6.8.5 Mirati Therapeutics Recent Developments/Updates
6.9 OncoGenex
6.9.1 OncoGenex Company Information
6.9.2 OncoGenex Description and Business Overview
6.9.3 OncoGenex Bladder Cancer Biologics Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 OncoGenex Bladder Cancer Biologics Product Portfolio
6.9.5 OncoGenex Recent Developments/Updates
6.10 Pfizer
6.10.1 Pfizer Company Information
6.10.2 Pfizer Description and Business Overview
6.10.3 Pfizer Bladder Cancer Biologics Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Pfizer Bladder Cancer Biologics Product Portfolio
6.10.5 Pfizer Recent Developments/Updates
6.11 Roche Holding
6.11.1 Roche Holding Company Information
6.11.2 Roche Holding Description and Business Overview
6.11.3 Roche Holding Bladder Cancer Biologics Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Roche Holding Bladder Cancer Biologics Product Portfolio
6.11.5 Roche Holding Recent Developments/Updates
6.12 Spectrum Pharmaceuticals
6.12.1 Spectrum Pharmaceuticals Company Information
6.12.2 Spectrum Pharmaceuticals Description and Business Overview
6.12.3 Spectrum Pharmaceuticals Bladder Cancer Biologics Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Spectrum Pharmaceuticals Bladder Cancer Biologics Product Portfolio
6.12.5 Spectrum Pharmaceuticals Recent Developments/Updates
6.13 Taiho Pharmaceutical
6.13.1 Taiho Pharmaceutical Company Information
6.13.2 Taiho Pharmaceutical Description and Business Overview
6.13.3 Taiho Pharmaceutical Bladder Cancer Biologics Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Taiho Pharmaceutical Bladder Cancer Biologics Product Portfolio
6.13.5 Taiho Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Bladder Cancer Biologics Industry Chain Analysis
7.2 Bladder Cancer Biologics Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Bladder Cancer Biologics Production Mode & Process Analysis
7.4 Bladder Cancer Biologics Sales and Marketing
7.4.1 Bladder Cancer Biologics Sales Channels
7.4.2 Bladder Cancer Biologics Distributors
7.5 Bladder Cancer Biologics Customer Analysis
8 Bladder Cancer Biologics Market Dynamics
8.1 Bladder Cancer Biologics Industry Trends
8.2 Bladder Cancer Biologics Market Drivers
8.3 Bladder Cancer Biologics Market Challenges
8.4 Bladder Cancer Biologics Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Bladder Cancer Biologics Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Bladder Cancer Biologics Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Bladder Cancer Biologics Market Competitive Situation by Manufacturers in 2025
Table 4. Global Bladder Cancer Biologics Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Bladder Cancer Biologics Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Bladder Cancer Biologics Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Bladder Cancer Biologics Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Bladder Cancer Biologics Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Bladder Cancer Biologics, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Bladder Cancer Biologics, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Bladder Cancer Biologics, Product Types and Applications
Table 12. Global Key Manufacturers of Bladder Cancer Biologics, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Bladder Cancer Biologics Companies by Tier (Tier 1, Tier 2, Tier 3), based on Bladder Cancer Biologics Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Bladder Cancer Biologics Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Bladder Cancer Biologics Sales by Region (K Units), 2021–2026
Table 18. Global Bladder Cancer Biologics Sales Market Share by Region (2021–2026)
Table 19. Global Bladder Cancer Biologics Sales by Region (K Units), 2027–2032
Table 20. Global Bladder Cancer Biologics Sales Market Share by Region (2027–2032)
Table 21. Global Bladder Cancer Biologics Revenue by Region (US$ Million), 2021–2026
Table 22. Global Bladder Cancer Biologics Revenue Market Share by Region (2021–2026)
Table 23. Global Bladder Cancer Biologics Revenue by Region (US$ Million), 2027–2032
Table 24. Global Bladder Cancer Biologics Revenue Market Share by Region (2027–2032)
Table 25. North America Bladder Cancer Biologics Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Bladder Cancer Biologics Sales by Country (K Units), 2021–2026
Table 27. North America Bladder Cancer Biologics Sales by Country (K Units), 2027–2032
Table 28. North America Bladder Cancer Biologics Revenue by Country (US$ Million), 2021–2026
Table 29. North America Bladder Cancer Biologics Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Bladder Cancer Biologics Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Bladder Cancer Biologics Sales by Country (K Units), 2021–2026
Table 32. Europe Bladder Cancer Biologics Sales by Country (K Units), 2027–2032
Table 33. Europe Bladder Cancer Biologics Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Bladder Cancer Biologics Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Bladder Cancer Biologics Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Bladder Cancer Biologics Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Bladder Cancer Biologics Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Bladder Cancer Biologics Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Bladder Cancer Biologics Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Bladder Cancer Biologics Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Bladder Cancer Biologics Sales by Country (K Units), 2021–2026
Table 42. Latin America Bladder Cancer Biologics Sales by Country (K Units), 2027–2032
Table 43. Latin America Bladder Cancer Biologics Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Bladder Cancer Biologics Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Bladder Cancer Biologics Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Bladder Cancer Biologics Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Bladder Cancer Biologics Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Bladder Cancer Biologics Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Bladder Cancer Biologics Revenue by Country (US$ Million), 2027–2032
Table 50. Global Bladder Cancer Biologics Sales (K Units) by Type (2021–2026)
Table 51. Global Bladder Cancer Biologics Sales (K Units) by Type (2027–2032)
Table 52. Global Bladder Cancer Biologics Sales Market Share by Type (2021–2026)
Table 53. Global Bladder Cancer Biologics Sales Market Share by Type (2027–2032)
Table 54. Global Bladder Cancer Biologics Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Bladder Cancer Biologics Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Bladder Cancer Biologics Revenue Market Share by Type (2021–2026)
Table 57. Global Bladder Cancer Biologics Revenue Market Share by Type (2027–2032)
Table 58. Global Bladder Cancer Biologics Price (US$/Unit) by Type (2021–2026)
Table 59. Global Bladder Cancer Biologics Price (US$/Unit) by Type (2027–2032)
Table 60. Global Bladder Cancer Biologics Sales (K Units) by Application (2021–2026)
Table 61. Global Bladder Cancer Biologics Sales (K Units) by Application (2027–2032)
Table 62. Global Bladder Cancer Biologics Sales Market Share by Application (2021–2026)
Table 63. Global Bladder Cancer Biologics Sales Market Share by Application (2027–2032)
Table 64. Global Bladder Cancer Biologics Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Bladder Cancer Biologics Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Bladder Cancer Biologics Revenue Market Share by Application (2021–2026)
Table 67. Global Bladder Cancer Biologics Revenue Market Share by Application (2027–2032)
Table 68. Global Bladder Cancer Biologics Price (US$/Unit) by Application (2021–2026)
Table 69. Global Bladder Cancer Biologics Price (US$/Unit) by Application (2027–2032)
Table 70. AstraZenenca Company Information
Table 71. AstraZenenca Description and Business Overview
Table 72. AstraZenenca Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. AstraZenenca Bladder Cancer Biologics Product
Table 74. AstraZenenca Recent Developments/Updates
Table 75. Bristol-Myers Squibb Company Company Information
Table 76. Bristol-Myers Squibb Company Description and Business Overview
Table 77. Bristol-Myers Squibb Company Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Bristol-Myers Squibb Company Bladder Cancer Biologics Product
Table 79. Bristol-Myers Squibb Company Recent Developments/Updates
Table 80. Chugai Pharmaceutical Company Information
Table 81. Chugai Pharmaceutical Description and Business Overview
Table 82. Chugai Pharmaceutical Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Chugai Pharmaceutical Bladder Cancer Biologics Product
Table 84. Chugai Pharmaceutical Recent Developments/Updates
Table 85. Cold Genesys Company Information
Table 86. Cold Genesys Description and Business Overview
Table 87. Cold Genesys Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Cold Genesys Bladder Cancer Biologics Product
Table 89. Cold Genesys Recent Developments/Updates
Table 90. Eli Lilly Company Information
Table 91. Eli Lilly Description and Business Overview
Table 92. Eli Lilly Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Eli Lilly Bladder Cancer Biologics Product
Table 94. Eli Lilly Recent Developments/Updates
Table 95. Nighthawk Biosciences Company Information
Table 96. Nighthawk Biosciences Description and Business Overview
Table 97. Nighthawk Biosciences Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Nighthawk Biosciences Bladder Cancer Biologics Product
Table 99. Nighthawk Biosciences Recent Developments/Updates
Table 100. Merck & Co Company Information
Table 101. Merck & Co Description and Business Overview
Table 102. Merck & Co Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Merck & Co Bladder Cancer Biologics Product
Table 104. Merck & Co Recent Developments/Updates
Table 105. Mirati Therapeutics Company Information
Table 106. Mirati Therapeutics Description and Business Overview
Table 107. Mirati Therapeutics Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Mirati Therapeutics Bladder Cancer Biologics Product
Table 109. Mirati Therapeutics Recent Developments/Updates
Table 110. OncoGenex Company Information
Table 111. OncoGenex Description and Business Overview
Table 112. OncoGenex Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. OncoGenex Bladder Cancer Biologics Product
Table 114. OncoGenex Recent Developments/Updates
Table 115. Pfizer Company Information
Table 116. Pfizer Description and Business Overview
Table 117. Pfizer Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Pfizer Bladder Cancer Biologics Product
Table 119. Pfizer Recent Developments/Updates
Table 120. Roche Holding Company Information
Table 121. Roche Holding Description and Business Overview
Table 122. Roche Holding Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Roche Holding Bladder Cancer Biologics Product
Table 124. Roche Holding Recent Developments/Updates
Table 125. Spectrum Pharmaceuticals Company Information
Table 126. Spectrum Pharmaceuticals Description and Business Overview
Table 127. Spectrum Pharmaceuticals Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Spectrum Pharmaceuticals Bladder Cancer Biologics Product
Table 129. Spectrum Pharmaceuticals Recent Developments/Updates
Table 130. Taiho Pharmaceutical Company Information
Table 131. Taiho Pharmaceutical Description and Business Overview
Table 132. Taiho Pharmaceutical Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Taiho Pharmaceutical Bladder Cancer Biologics Product
Table 134. Taiho Pharmaceutical Recent Developments/Updates
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. Bladder Cancer Biologics Distributors List
Table 138. Bladder Cancer Biologics Customers List
Table 139. Bladder Cancer Biologics Market Trends
Table 140. Bladder Cancer Biologics Market Drivers
Table 141. Bladder Cancer Biologics Market Challenges
Table 142. Bladder Cancer Biologics Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
Table 146. Authors List of This Report
List of Figures
Figure 1. Product Picture of Bladder Cancer Biologics
Figure 2. Global Bladder Cancer Biologics Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Bladder Cancer Biologics Market Share by Type: 2025 & 2032
Figure 4. PD-1 Inhibitors Product Picture
Figure 5. CTLA-4 Inhibitors Product Picture
Figure 6. FGFR Inhibitors Product Picture
Figure 7. Others Product Picture
Figure 8. Global Bladder Cancer Biologics Market Value by Application (US$ Million), 2021–2032
Figure 9. Global Bladder Cancer Biologics Market Share by Application: 2025 & 2032
Figure 10. Hospital
Figure 11. Specialty Clinic
Figure 12. Other
Figure 13. Global Bladder Cancer Biologics Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 14. Global Bladder Cancer Biologics Market Size (US$ Million), 2021–2032
Figure 15. Global Bladder Cancer Biologics Sales (K Units), 2021–2032
Figure 16. Global Bladder Cancer Biologics Average Price (US$/Unit), 2021–2032
Figure 17. Bladder Cancer Biologics Report Years Considered
Figure 18. Bladder Cancer Biologics Sales Share by Manufacturers in 2025
Figure 19. Global Bladder Cancer Biologics Revenue Share by Manufacturers in 2025
Figure 20. Top 5 and Top 10 Global Bladder Cancer Biologics Players: Market Share by Revenue in Bladder Cancer Biologics in 2025
Figure 21. Bladder Cancer Biologics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 22. Global Bladder Cancer Biologics Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 23. North America Bladder Cancer Biologics Sales Market Share by Country (2021–2032)
Figure 24. North America Bladder Cancer Biologics Revenue Market Share by Country (2021–2032)
Figure 25. United States Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Canada Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. Europe Bladder Cancer Biologics Sales Market Share by Country (2021–2032)
Figure 28. Europe Bladder Cancer Biologics Revenue Market Share by Country (2021–2032)
Figure 29. Germany Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. France Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. U.K. Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Italy Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Russia Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Asia Pacific Bladder Cancer Biologics Sales Market Share by Region (2021–2032)
Figure 35. Asia Pacific Bladder Cancer Biologics Revenue Market Share by Region (2021–2032)
Figure 36. China Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Japan Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. South Korea Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. India Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Australia Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. China Taiwan Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Southeast Asia Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Latin America Bladder Cancer Biologics Sales Market Share by Country (2021–2032)
Figure 44. Latin America Bladder Cancer Biologics Revenue Market Share by Country (2021–2032)
Figure 45. Mexico Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Brazil Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Argentina Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Colombia Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Middle East and Africa Bladder Cancer Biologics Sales Market Share by Country (2021–2032)
Figure 50. Middle East and Africa Bladder Cancer Biologics Revenue Market Share by Country (2021–2032)
Figure 51. Turkey Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Saudi Arabia Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. UAE Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Global Sales Market Share of Bladder Cancer Biologics by Type (2021–2032)
Figure 55. Global Revenue Market Share of Bladder Cancer Biologics by Type (2021–2032)
Figure 56. Global Bladder Cancer Biologics Price (US$/Unit) by Type (2021–2032)
Figure 57. Global Sales Market Share of Bladder Cancer Biologics by Application (2021–2032)
Figure 58. Global Revenue Market Share of Bladder Cancer Biologics by Application (2021–2032)
Figure 59. Global Bladder Cancer Biologics Price (US$/Unit) by Application (2021–2032)
Figure 60. Bladder Cancer Biologics Value Chain
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Table 1. Global Bladder Cancer Biologics Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Bladder Cancer Biologics Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Bladder Cancer Biologics Market Competitive Situation by Manufacturers in 2025
Table 4. Global Bladder Cancer Biologics Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Bladder Cancer Biologics Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Bladder Cancer Biologics Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Bladder Cancer Biologics Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Bladder Cancer Biologics Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Bladder Cancer Biologics, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Bladder Cancer Biologics, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Bladder Cancer Biologics, Product Types and Applications
Table 12. Global Key Manufacturers of Bladder Cancer Biologics, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Bladder Cancer Biologics Companies by Tier (Tier 1, Tier 2, Tier 3), based on Bladder Cancer Biologics Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Bladder Cancer Biologics Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Bladder Cancer Biologics Sales by Region (K Units), 2021–2026
Table 18. Global Bladder Cancer Biologics Sales Market Share by Region (2021–2026)
Table 19. Global Bladder Cancer Biologics Sales by Region (K Units), 2027–2032
Table 20. Global Bladder Cancer Biologics Sales Market Share by Region (2027–2032)
Table 21. Global Bladder Cancer Biologics Revenue by Region (US$ Million), 2021–2026
Table 22. Global Bladder Cancer Biologics Revenue Market Share by Region (2021–2026)
Table 23. Global Bladder Cancer Biologics Revenue by Region (US$ Million), 2027–2032
Table 24. Global Bladder Cancer Biologics Revenue Market Share by Region (2027–2032)
Table 25. North America Bladder Cancer Biologics Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Bladder Cancer Biologics Sales by Country (K Units), 2021–2026
Table 27. North America Bladder Cancer Biologics Sales by Country (K Units), 2027–2032
Table 28. North America Bladder Cancer Biologics Revenue by Country (US$ Million), 2021–2026
Table 29. North America Bladder Cancer Biologics Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Bladder Cancer Biologics Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Bladder Cancer Biologics Sales by Country (K Units), 2021–2026
Table 32. Europe Bladder Cancer Biologics Sales by Country (K Units), 2027–2032
Table 33. Europe Bladder Cancer Biologics Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Bladder Cancer Biologics Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Bladder Cancer Biologics Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Bladder Cancer Biologics Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Bladder Cancer Biologics Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Bladder Cancer Biologics Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Bladder Cancer Biologics Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Bladder Cancer Biologics Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Bladder Cancer Biologics Sales by Country (K Units), 2021–2026
Table 42. Latin America Bladder Cancer Biologics Sales by Country (K Units), 2027–2032
Table 43. Latin America Bladder Cancer Biologics Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Bladder Cancer Biologics Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Bladder Cancer Biologics Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Bladder Cancer Biologics Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Bladder Cancer Biologics Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Bladder Cancer Biologics Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Bladder Cancer Biologics Revenue by Country (US$ Million), 2027–2032
Table 50. Global Bladder Cancer Biologics Sales (K Units) by Type (2021–2026)
Table 51. Global Bladder Cancer Biologics Sales (K Units) by Type (2027–2032)
Table 52. Global Bladder Cancer Biologics Sales Market Share by Type (2021–2026)
Table 53. Global Bladder Cancer Biologics Sales Market Share by Type (2027–2032)
Table 54. Global Bladder Cancer Biologics Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Bladder Cancer Biologics Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Bladder Cancer Biologics Revenue Market Share by Type (2021–2026)
Table 57. Global Bladder Cancer Biologics Revenue Market Share by Type (2027–2032)
Table 58. Global Bladder Cancer Biologics Price (US$/Unit) by Type (2021–2026)
Table 59. Global Bladder Cancer Biologics Price (US$/Unit) by Type (2027–2032)
Table 60. Global Bladder Cancer Biologics Sales (K Units) by Application (2021–2026)
Table 61. Global Bladder Cancer Biologics Sales (K Units) by Application (2027–2032)
Table 62. Global Bladder Cancer Biologics Sales Market Share by Application (2021–2026)
Table 63. Global Bladder Cancer Biologics Sales Market Share by Application (2027–2032)
Table 64. Global Bladder Cancer Biologics Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Bladder Cancer Biologics Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Bladder Cancer Biologics Revenue Market Share by Application (2021–2026)
Table 67. Global Bladder Cancer Biologics Revenue Market Share by Application (2027–2032)
Table 68. Global Bladder Cancer Biologics Price (US$/Unit) by Application (2021–2026)
Table 69. Global Bladder Cancer Biologics Price (US$/Unit) by Application (2027–2032)
Table 70. AstraZenenca Company Information
Table 71. AstraZenenca Description and Business Overview
Table 72. AstraZenenca Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. AstraZenenca Bladder Cancer Biologics Product
Table 74. AstraZenenca Recent Developments/Updates
Table 75. Bristol-Myers Squibb Company Company Information
Table 76. Bristol-Myers Squibb Company Description and Business Overview
Table 77. Bristol-Myers Squibb Company Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Bristol-Myers Squibb Company Bladder Cancer Biologics Product
Table 79. Bristol-Myers Squibb Company Recent Developments/Updates
Table 80. Chugai Pharmaceutical Company Information
Table 81. Chugai Pharmaceutical Description and Business Overview
Table 82. Chugai Pharmaceutical Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Chugai Pharmaceutical Bladder Cancer Biologics Product
Table 84. Chugai Pharmaceutical Recent Developments/Updates
Table 85. Cold Genesys Company Information
Table 86. Cold Genesys Description and Business Overview
Table 87. Cold Genesys Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Cold Genesys Bladder Cancer Biologics Product
Table 89. Cold Genesys Recent Developments/Updates
Table 90. Eli Lilly Company Information
Table 91. Eli Lilly Description and Business Overview
Table 92. Eli Lilly Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Eli Lilly Bladder Cancer Biologics Product
Table 94. Eli Lilly Recent Developments/Updates
Table 95. Nighthawk Biosciences Company Information
Table 96. Nighthawk Biosciences Description and Business Overview
Table 97. Nighthawk Biosciences Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Nighthawk Biosciences Bladder Cancer Biologics Product
Table 99. Nighthawk Biosciences Recent Developments/Updates
Table 100. Merck & Co Company Information
Table 101. Merck & Co Description and Business Overview
Table 102. Merck & Co Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Merck & Co Bladder Cancer Biologics Product
Table 104. Merck & Co Recent Developments/Updates
Table 105. Mirati Therapeutics Company Information
Table 106. Mirati Therapeutics Description and Business Overview
Table 107. Mirati Therapeutics Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Mirati Therapeutics Bladder Cancer Biologics Product
Table 109. Mirati Therapeutics Recent Developments/Updates
Table 110. OncoGenex Company Information
Table 111. OncoGenex Description and Business Overview
Table 112. OncoGenex Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. OncoGenex Bladder Cancer Biologics Product
Table 114. OncoGenex Recent Developments/Updates
Table 115. Pfizer Company Information
Table 116. Pfizer Description and Business Overview
Table 117. Pfizer Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Pfizer Bladder Cancer Biologics Product
Table 119. Pfizer Recent Developments/Updates
Table 120. Roche Holding Company Information
Table 121. Roche Holding Description and Business Overview
Table 122. Roche Holding Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Roche Holding Bladder Cancer Biologics Product
Table 124. Roche Holding Recent Developments/Updates
Table 125. Spectrum Pharmaceuticals Company Information
Table 126. Spectrum Pharmaceuticals Description and Business Overview
Table 127. Spectrum Pharmaceuticals Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Spectrum Pharmaceuticals Bladder Cancer Biologics Product
Table 129. Spectrum Pharmaceuticals Recent Developments/Updates
Table 130. Taiho Pharmaceutical Company Information
Table 131. Taiho Pharmaceutical Description and Business Overview
Table 132. Taiho Pharmaceutical Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Taiho Pharmaceutical Bladder Cancer Biologics Product
Table 134. Taiho Pharmaceutical Recent Developments/Updates
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. Bladder Cancer Biologics Distributors List
Table 138. Bladder Cancer Biologics Customers List
Table 139. Bladder Cancer Biologics Market Trends
Table 140. Bladder Cancer Biologics Market Drivers
Table 141. Bladder Cancer Biologics Market Challenges
Table 142. Bladder Cancer Biologics Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
Table 146. Authors List of This Report
List of Figures
Figure 1. Product Picture of Bladder Cancer Biologics
Figure 2. Global Bladder Cancer Biologics Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Bladder Cancer Biologics Market Share by Type: 2025 & 2032
Figure 4. PD-1 Inhibitors Product Picture
Figure 5. CTLA-4 Inhibitors Product Picture
Figure 6. FGFR Inhibitors Product Picture
Figure 7. Others Product Picture
Figure 8. Global Bladder Cancer Biologics Market Value by Application (US$ Million), 2021–2032
Figure 9. Global Bladder Cancer Biologics Market Share by Application: 2025 & 2032
Figure 10. Hospital
Figure 11. Specialty Clinic
Figure 12. Other
Figure 13. Global Bladder Cancer Biologics Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 14. Global Bladder Cancer Biologics Market Size (US$ Million), 2021–2032
Figure 15. Global Bladder Cancer Biologics Sales (K Units), 2021–2032
Figure 16. Global Bladder Cancer Biologics Average Price (US$/Unit), 2021–2032
Figure 17. Bladder Cancer Biologics Report Years Considered
Figure 18. Bladder Cancer Biologics Sales Share by Manufacturers in 2025
Figure 19. Global Bladder Cancer Biologics Revenue Share by Manufacturers in 2025
Figure 20. Top 5 and Top 10 Global Bladder Cancer Biologics Players: Market Share by Revenue in Bladder Cancer Biologics in 2025
Figure 21. Bladder Cancer Biologics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 22. Global Bladder Cancer Biologics Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 23. North America Bladder Cancer Biologics Sales Market Share by Country (2021–2032)
Figure 24. North America Bladder Cancer Biologics Revenue Market Share by Country (2021–2032)
Figure 25. United States Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Canada Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. Europe Bladder Cancer Biologics Sales Market Share by Country (2021–2032)
Figure 28. Europe Bladder Cancer Biologics Revenue Market Share by Country (2021–2032)
Figure 29. Germany Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. France Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. U.K. Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Italy Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Russia Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Asia Pacific Bladder Cancer Biologics Sales Market Share by Region (2021–2032)
Figure 35. Asia Pacific Bladder Cancer Biologics Revenue Market Share by Region (2021–2032)
Figure 36. China Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Japan Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. South Korea Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. India Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Australia Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. China Taiwan Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Southeast Asia Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Latin America Bladder Cancer Biologics Sales Market Share by Country (2021–2032)
Figure 44. Latin America Bladder Cancer Biologics Revenue Market Share by Country (2021–2032)
Figure 45. Mexico Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Brazil Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Argentina Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Colombia Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Middle East and Africa Bladder Cancer Biologics Sales Market Share by Country (2021–2032)
Figure 50. Middle East and Africa Bladder Cancer Biologics Revenue Market Share by Country (2021–2032)
Figure 51. Turkey Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Saudi Arabia Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. UAE Bladder Cancer Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Global Sales Market Share of Bladder Cancer Biologics by Type (2021–2032)
Figure 55. Global Revenue Market Share of Bladder Cancer Biologics by Type (2021–2032)
Figure 56. Global Bladder Cancer Biologics Price (US$/Unit) by Type (2021–2032)
Figure 57. Global Sales Market Share of Bladder Cancer Biologics by Application (2021–2032)
Figure 58. Global Revenue Market Share of Bladder Cancer Biologics by Application (2021–2032)
Figure 59. Global Bladder Cancer Biologics Price (US$/Unit) by Application (2021–2032)
Figure 60. Bladder Cancer Biologics Value Chain
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Natural Cocoa Extracts Market Research Report 2026
May 01, 26
Global Semiconductor Switched Mode Power Supply Market Research Report 2026
May 01, 26
Global Silicone Coated Spandrel Glass Market Research Report 2026
May 01, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232